Abstract:The expression of survivin, an inhibitor of apoptosis can be seen in most tumors and is correlated with the angiogenic factor vascular endothelial growth factor (VEGF). But little is known about their contribution in small-cell lung cancer (SCLC). This study was designed to investigate the expression of survivin and VEGF in SCLC, and to explore their correlation with clinical-pathological feature and prognosis. Forty-five patients with pathological histology of SCLC were entered into this study. Forty-five cases of matched adjacent non-tumor samples and 10 samples of operated patients with benign lung tumor were also included as control. The expression of survivin and VEGF was detected by immunohistochemistry (IHC, SP). These two sets of data were processed and tested for correlation with major patients' characteristics, and overall survival. The correlations between survivin and VEGF expressions and the clinical-pathological features were evaluated by chi-square test. The correlation between survivin and VEGF expressions was analyzed by Spearman's rank correlation test; the overall survival was analyzed by the Kaplan-Meier method; and the relationship between clinical and pathological features and overall survival was analyzed by the Cox proportional hazard models. Positive expression rate of survivin and VEGF was significantly higher in SCLC than those of adjacent non-tumor tissues and benign lung tumor tissues (73.3 vs. 15.6 vs. 0 %, P < 0.05) and (75.6 vs. 20 vs. 0 %, P < 0.05), respectively. Survivin and VEGF expressions were significantly associated with lymph node metastasis (P = 0.003, 0.011) and clinical stage (P = 0.006, 0.021). The expression of survivin was significantly coincident with the expression of VEGF (r = 0.644, P = 0.000). The median overall survival in survivin positive group and VEGF positive group was significantly shorter than those in survivin negative and VEGF negative group, respectively (log-rank P = 0.000). Moreover, multivariate analysis showed that survivin expression (HR 0.224; 95 % CI 0.074-0.675; P = 0.008) and VEGF expression (HR 0.172; 95 % CI 0.054-0.559; P = 0.003) were statistically independent predictive factors of poorer prognosis for SCLC patients. Our results indicated that survivin and VEGF were over-expressed in small-cell lung cancer, each of them may be an independent poor prognostic factor.

Over-expression of Small Ubiquitin-Like Modifier Proteases 1 Predicts Chemo-Sensitivity and Poor Survival in Non-Small Cell Lung Cancer.

Sumo-1 Expression Modulates Non-Small Cell Lung Cancer Progression

Identification of Key Genes and Evaluation of Clinical Outcomes in Lung Squamous Cell Carcinoma Using Integrated Bioinformatics Analysis

A gene expression signature predicts survival of patients with stage I non-small cell lung cancer.

The Prognostic Value of Expression of Multiple Genes on Resected Non-Small Cell Lung Cancer Tissues

Identification of Candidate Biomarkers Correlated With the Pathogenesis and Prognosis of Non-small Cell Lung Cancer via Integrated Bioinformatics Analysis

ERCC1, RRM1 and BRCA1 Mrna Expression Levels and Clinical Outcome of Advanced Non-Small Cell Lung Cancer.

Overexpression Of Deubiquitinating Enzyme Usp28 Promoted Non-Small Cell Lung Cancer Growth

Expression of SUMO1P3 Compared with SUMO1 is an Independent Predictor of Patient Outcome in Lung Adenocarcinoma.

SENP1 Promotes Proliferation of Clear Cell Renal Cell Carcinoma Through Activation of Glycolysis.

SUMO1 Promotes the Proliferation and Invasion of Non‐small Cell Lung Cancer Cells by Regulating NF‐κB

SUMO-specific Protease 1 Regulates the in Vitro and in Vivo Growth of Colon Cancer Cells with the Upregulated Expression of CDK Inhibitors.

SUMO-specific Protease 1 Promotes Prostate Cancer Progression and Metastasis.

The Overexpression of 14‐3‐3ζ and Hsp27 Promotes Non–small Cell Lung Cancer Progression

SUMO-Activating Enzyme Subunit 1 Is Associated with Poor Prognosis, Tumor Progression, and Radio-Resistance in Colorectal Cancer

MUC1 Overexpression Predicts Worse Survival in Patients with Non-Small Cell Lung Cancer: Evidence from an Updated Meta-Analysis.

Suppressing SENP1 Inhibits Esophageal Squamous Carcinoma Cell Growth Via SIRT6 SUMOylation

Over-expression of Survivin and VEGF in Small-Cell Lung Cancer May Predict the Poorer Prognosis.

SUMOylation of Vascular Endothelial Growth Factor Receptor 2 Inhibits the Proliferation, Migration, and Angiogenesis Signaling Pathway in Non-Small Cell Lung Cancer

PD-L1 Expression and Comprehensive Molecular Profiling Predict Survival in Nonsmall Cell Lung Cancer: A Real-World Study of a Large Chinese Cohort

The USP21/YY1/SNHG16 Axis Contributes to Tumor Proliferation, Migration, and Invasion of Non-Small-cell Lung Cancer